We serve Chemical Name:(S)-H-β-Phe(4-CN)-OH CAS:718596-77-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(S)-H-β-Phe(4-CN)-OH
CAS.NO:718596-77-1
Synonyms:(3S)-3-Amino-3-(4-cyanophenyl)propanoic acid;3-Amino-3-(4-cyanophenyl)propanoic acid;Benzenepropanoic acid, β-amino-4-cyano-;Benzenepropanoic acid, β-amino-4-cyano-, (βS)-;(S)-H-β-Phe(4-CN)-OH
Molecular Formula:C10H10N2O2
Molecular Weight:190.199
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:395.4±37.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.596
PSA:87.11000
Exact Mass:190.074234
LogP:0.35
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like (3S)-3-Amino-3-(4-cyanophenyl)propanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(S)-H-β-Phe(4-CN)-OH physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(3S)-3-Amino-3-(4-cyanophenyl)propanoic acid Use and application,3-Amino-3-(4-cyanophenyl)propanoic acid technical grade,usp/ep/jp grade.
Related News: The company forecasts that the 70-strong team will grow by around 50% in the next three years to support its clinical and commercial API manufacturing capabilities. L-Arginine,L-threonyl-L-valyl-L-tryptophylglycyl-L-isoleucyl-L-leucyl-L-prolyl-L-arginyl-L-lysyl- manufacturers The announcement comes on top of Recipharm’s move into Morocco, which was fueled by local pledges of $500 million. The new facility under construction and due for completion in 2023 will employ 300 and have a capacity of 300 million units annually. Cyclopentadien-carbonsaeure-N,N-dimethylamid suppliers Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. rel-3-((1R,4S,6R)-2-azabicyclo[2.2.2]octan-6-yl)-4-(pentyloxy)-1,2,5-thiadiazole vendor & factory Grégoire Boutonnet, Chief Operating Officer of NOVA, said: “I am thrilled to be joining the NOVA team at this exciting period of growth as we launch the Jinkō platform towards wider adoption in the clinical trial development space. ,Charles River looks forward to continuing its ongoing partnership with AstraZeneca. It was great to join the team today, to see the facility for myself and congratulate them on this really significant expansion, which will see an €8m investment, creating 90 new jobs for Mayo.
